anti-PD-L1 antibody
ApprovedSmall molecule
anti-PD-L1 antibody is one of 83 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Approved.
3
Indications
3
Total Trials
1
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
241 competitors in Esophageal Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Camptosar
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Eloxatin
TevaPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Tecentriq
RochePhase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Bayer Aspirin
BayerPhase 3
Taxotere
AAvyxa
Phase 3
Theraplaza
BBiotech Pharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Urothelial Carcinoma1 trial
Esophageal Squamous Cell Carcinoma1 trial
Chronic Hepatitis b1 trial
ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection
Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Approved·NCT07573943·150 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti-PD-L1 antibody. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- LLee's Pharmaceutical Limited